Prevention and Treatment of Osteoporosis in Postmenopausal Women: A Review
Links shared publicly online about this topic.
- 67total visits
Prevention and Treatment of Osteoporosis in Postmenopausal Women: A Review
View full resource at nursingcenter.com
Tags: Osteoporosis, Women's Health, Nursing Professions, Nurse, Nursing
Most Recently Shared on August 17, 2011 at 2:12 am By:
New CE articles to share...first up ~ Prevention and Treatment of Osteoporosis in Postmenopausal Women: A Review http://t.co/mK1g6oh (AJN)
Exercise for preventing and treating osteoporosis in postmenopausal women
www2.cochrane.org — “Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD000333. DOI: 10.1002/14651858.CD000333.pub2” View full resource at www2.cochrane.org
Most Recently Shared on July 14, 2011 at 7:20 pm By:
Wiley Health Medical Health Site
RT @cochranecollab: New #Cochrane review: Exercise for preventing and treating osteoporosis in postmenopausal women: http://ow.ly/5DQ20
First EffRx NDA Accepted for Filing by the FDA
drugs.com — “EX101 (alendronate sodium) is a new drug in development for the prevention and treatment of osteoporosis in postmenopausal women. EX101 information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on May 13, 2011 at 12:05 am By:
Drugs and Devices OW OW Health
First EffRx NDA Accepted for Filing by the FDA: LAUSANNE, Switzerland--(BUSINESS WIRE)--May 11, 2011 - Eff... http://bit.ly/lanXr3 #drug
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
annonc.oxfordjournals.org — “Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment” View full resource at annonc.oxfordjournals.org
Most Recently Shared on March 21, 2011 at 2:25 pm By:
Oxford Journals(OUP) Medical Journal
RT @Annals_Oncology: Free review: Management of aromatase inhibitor-associated bone loss in.. women with breast #cancer http://bit.ly/fahw4O
AACE, USPSTF issue recommendations for osteoporosis screening, treatment in postmenopausal women
endocrinetoday.com — “To prevent and properly treat osteoporosis, the American Academy of Clinical Endocrinologists and the US Preventive Services Task Force recommen” View full resource at endocrinetoday.com
Most Recently Shared on January 17, 2011 at 10:16 pm By:
#AACE, #USPSTF issue recommendations for #osteoporosis screening, treatment in #postmenopausal women http://bit.ly/giAhXi
FDA grants denosumab priority review for cancer-related bone loss
endocrinetoday.com — “The FDA has granted denosumab, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures, priority revi” View full resource at endocrinetoday.com
Most Recently Shared on July 19, 2010 at 2:13 pm By:
#FDA grants #denosumab priority review for cancer-related bone loss http://ow.ly/2docw
EVISTA improves bone quality as measured by HRpQCT: IIT
news-medical.net — “Interim data from a prospective Investigator Initiated Trial presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the high-resolution peripheral quantitative computed tomography.” View full resource at news-medical.net
Most Recently Shared on June 28, 2010 at 10:31 am By:
EVISTA improves bone quality as measured by HRpQCT: IIT: Interim data from a prospective Investigator Initiated Tr... http://bit.ly/dvfcCs
Skull Bone's Resistance To Osteoporosis Opens Way For New Treatment, Prevention
medicalnewstoday.com — “Uk scientists curious to discover why unlike the weight-bearing bone in our limbs, skull bone does not get thin as it ages, even in post-menopausal women, have found some quite remarkable differ” View full resource at medicalnewstoday.com
Most Recently Shared on December 21, 2009 at 10:06 pm By:
Skull Bone's Resistance To Osteoporosis Opens Way For New Treatment, Prevention http://mnt.to/3vKJ
Bazedoxifene May Be Safe for Postmenopausal Women With Osteoporosis - WEGO Health
community.wegohealth.com — “Bazedoxifene May Be Safe for Postmenopausal Women With Osteoporosis Bazedoxifene May Be Safe for Postmenopausal Women With Osteoporosis - therapeutic option for the prevention and treatment of postmenopausal osteoporosis The selective estrogen receptor modulator bazedoxifene may be safe for postmenopausal women with osteoporosis, according to the results of a randomized, double-blind, placebo-controlled phase 3 trial reported in the November/December issue of Menopause. Although current pharmaco” View full resource at community.wegohealth.com
Most Recently Shared on December 11, 2009 at 2:23 am By:
Our Aloe Business Health Business
Bazedoxifene May Be Safe for Postmenopausal Women With Osteoporosis http://bit.ly/8BLMqd
FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women
news-medical.net — “Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.” View full resource at news-medical.net
Most Recently Shared on June 1, 2009 at 2:02 pm By:
Osteoporosis News: FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal w.. http://tinyurl.com/ktja8m
FDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing
novartis.com — “Basel, June 1, 2009 - Reclast (zoledronic acid 5 mg) Injection[*] has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose[1]. Reclast, or Aclasta as it is known outside the US, is already approved in more than 80 countries including the US and EU as a once-yearly infusion for the treatment of postmenopausal osteoporosis[1],[4].” View full resource at novartis.com
Most Recently Shared on June 1, 2009 at 5:36 am By:
FDA approves Reclast® to prevent osteoporosis in postmenopausal women with convenient less frequent dosing: http://twurl.nl/po8fan
Advertisement
